首页 > 最新文献

European urology oncology最新文献

英文 中文
Prediction of Clinically Significant Prostate Cancer by a Specific Collagen-related Transcriptome, Proteome, and Urinome Signature. 通过与胶原蛋白相关的特定转录组、蛋白质组和尿液组特征预测具有临床意义的前列腺癌。
IF 8.2 1区 医学 Q1 ONCOLOGY Pub Date : 2024-06-07 DOI: 10.1016/j.euo.2024.05.014
Isabel Heidegger, Maria Frantzi, Stefan Salcher, Piotr Tymoszuk, Agnieszka Martowicz, Enrique Gomez-Gomez, Ana Blanca, Guillermo Lendinez Cano, Agnieszka Latosinska, Harald Mischak, Antonia Vlahou, Christian Langer, Friedrich Aigner, Martin Puhr, Anne Krogsdam, Zlatko Trajanoski, Dominik Wolf, Andreas Pircher

Background and objective: While collagen density has been associated with poor outcomes in various cancers, its role in prostate cancer (PCa) remains elusive. Our aim was to analyze collagen-related transcriptomic, proteomic, and urinome alterations in the context of detection of clinically significant PCa (csPCa, International Society of Urological Pathology [ISUP] grade group ≥2).

Methods: Comprehensive analyses for PCa transcriptome (n = 1393), proteome (n = 104), and urinome (n = 923) data sets focused on 55 collagen-related genes. Investigation of the cellular source of collagen-related transcripts via single-cell RNA sequencing was conducted. Statistical evaluations, clustering, and machine learning models were used for data analysis to identify csPCa signatures.

Key findings and limitations: Differential expression of 30 of 55 collagen-related genes and 34 proteins was confirmed in csPCa in comparison to benign prostate tissue or ISUP 1 cancer. A collagen-high cancer cluster exhibited distinct cellular and molecular characteristics, including fibroblast and endothelial cell infiltration, intense extracellular matrix turnover, and enhanced growth factor and inflammatory signaling. Robust collagen-based machine learning models were established to identify csPCa. The models outcompeted prostate-specific antigen (PSA) and age, showing comparable performance to multiparametric magnetic resonance imaging (mpMRI) in predicting csPCa. Of note, the urinome-based collagen model identified four of five csPCa cases among patients with Prostate Imaging-Reporting and Data System (PI-IRADS) 3 lesions, for which the presence of csPCa is considered equivocal. The retrospective character of the study is a limitation.

Conclusions and clinical implications: Collagen-related transcriptome, proteome, and urinome signatures exhibited superior accuracy in detecting csPCa in comparison to PSA and age. The collagen signatures, especially in cases of ambiguous lesions on mpMRI, successfully identified csPCa and could potentially reduce unnecessary biopsies. The urinome-based collagen signature represents a promising liquid biopsy tool that requires prospective evaluation to improve the potential of this collagen-based approach to enhance diagnostic precision in PCa for risk stratification and guiding personalized interventions.

Patient summary: In our study, collagen-related alterations in tissue, and urine were able to predict the presence of clinically significant prostate cancer at primary diagnosis.

背景和目的:虽然胶原蛋白密度与多种癌症的不良预后有关,但其在前列腺癌(PCa)中的作用仍难以捉摸。我们的目的是在检测有临床意义的 PCa(csPCa,国际泌尿病理学会 [ISUP] 等级组≥2)时分析与胶原相关的转录组、蛋白质组和尿液组改变:对 PCa 转录组(n = 1393)、蛋白质组(n = 104)和尿液组(n = 923)数据集进行综合分析,重点研究 55 个胶原蛋白相关基因。通过单细胞 RNA 测序调查了胶原蛋白相关转录本的细胞来源。数据分析采用了统计评估、聚类和机器学习模型,以确定 csPCa 特征:与良性前列腺组织或 ISUP 1 癌症相比,55 个胶原蛋白相关基因中的 30 个基因和 34 种蛋白质在 csPCa 中被证实存在差异表达。胶原蛋白含量高的癌症集群表现出独特的细胞和分子特征,包括成纤维细胞和内皮细胞浸润、细胞外基质剧烈周转以及生长因子和炎症信号增强。建立了基于胶原蛋白的强大机器学习模型来识别 csPCa。这些模型在预测 csPCa 方面的表现优于前列腺特异性抗原(PSA)和年龄,可与多参数磁共振成像(mpMRI)相媲美。值得注意的是,在前列腺成像报告和数据系统(PI-IRADS)3 级病变的患者中,基于尿液的胶原蛋白模型发现了五例 csPCa 中的四例,而 csPCa 的存在被认为是模棱两可的。该研究的回顾性是其局限性之一:与 PSA 和年龄相比,胶原蛋白相关的转录组、蛋白质组和尿液组特征在检测 csPCa 方面表现出更高的准确性。胶原蛋白特征,尤其是在 mpMRI 显示病变不明确的情况下,能成功识别 csPCa,并有可能减少不必要的活检。基于尿液组的胶原蛋白特征是一种很有前景的液体活检工具,需要进行前瞻性评估,以提高这种基于胶原蛋白的方法的潜力,从而提高 PCa 诊断的精确度,用于风险分层和指导个性化干预。患者总结:在我们的研究中,组织和尿液中与胶原蛋白相关的改变能够预测初诊时是否存在有临床意义的前列腺癌。
{"title":"Prediction of Clinically Significant Prostate Cancer by a Specific Collagen-related Transcriptome, Proteome, and Urinome Signature.","authors":"Isabel Heidegger, Maria Frantzi, Stefan Salcher, Piotr Tymoszuk, Agnieszka Martowicz, Enrique Gomez-Gomez, Ana Blanca, Guillermo Lendinez Cano, Agnieszka Latosinska, Harald Mischak, Antonia Vlahou, Christian Langer, Friedrich Aigner, Martin Puhr, Anne Krogsdam, Zlatko Trajanoski, Dominik Wolf, Andreas Pircher","doi":"10.1016/j.euo.2024.05.014","DOIUrl":"https://doi.org/10.1016/j.euo.2024.05.014","url":null,"abstract":"<p><strong>Background and objective: </strong>While collagen density has been associated with poor outcomes in various cancers, its role in prostate cancer (PCa) remains elusive. Our aim was to analyze collagen-related transcriptomic, proteomic, and urinome alterations in the context of detection of clinically significant PCa (csPCa, International Society of Urological Pathology [ISUP] grade group ≥2).</p><p><strong>Methods: </strong>Comprehensive analyses for PCa transcriptome (n = 1393), proteome (n = 104), and urinome (n = 923) data sets focused on 55 collagen-related genes. Investigation of the cellular source of collagen-related transcripts via single-cell RNA sequencing was conducted. Statistical evaluations, clustering, and machine learning models were used for data analysis to identify csPCa signatures.</p><p><strong>Key findings and limitations: </strong>Differential expression of 30 of 55 collagen-related genes and 34 proteins was confirmed in csPCa in comparison to benign prostate tissue or ISUP 1 cancer. A collagen-high cancer cluster exhibited distinct cellular and molecular characteristics, including fibroblast and endothelial cell infiltration, intense extracellular matrix turnover, and enhanced growth factor and inflammatory signaling. Robust collagen-based machine learning models were established to identify csPCa. The models outcompeted prostate-specific antigen (PSA) and age, showing comparable performance to multiparametric magnetic resonance imaging (mpMRI) in predicting csPCa. Of note, the urinome-based collagen model identified four of five csPCa cases among patients with Prostate Imaging-Reporting and Data System (PI-IRADS) 3 lesions, for which the presence of csPCa is considered equivocal. The retrospective character of the study is a limitation.</p><p><strong>Conclusions and clinical implications: </strong>Collagen-related transcriptome, proteome, and urinome signatures exhibited superior accuracy in detecting csPCa in comparison to PSA and age. The collagen signatures, especially in cases of ambiguous lesions on mpMRI, successfully identified csPCa and could potentially reduce unnecessary biopsies. The urinome-based collagen signature represents a promising liquid biopsy tool that requires prospective evaluation to improve the potential of this collagen-based approach to enhance diagnostic precision in PCa for risk stratification and guiding personalized interventions.</p><p><strong>Patient summary: </strong>In our study, collagen-related alterations in tissue, and urine were able to predict the presence of clinically significant prostate cancer at primary diagnosis.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141293234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
International Variations in Adherence to Quality Metrics for Locoregional Prostate Cancer. 遵守局部前列腺癌质量标准的国际差异。
IF 8.2 1区 医学 Q1 ONCOLOGY Pub Date : 2024-06-07 DOI: 10.1016/j.euo.2024.05.015
Adam B Weiner, Anissa V Nguyen, Amar U Kishan, Robert E Reiter, Mark S Litwin

Background and objective: Adherence to guideline recommendations can improve the quality of care for patients with prostate cancer (PCa). Our aim was to assess adherence to guidelines for locoregional PCa by international region.

Methods: The study cohort comprised patients diagnosed with locoregional PCa in the 10-country Movember TrueNTH Global Registry (n = 62 688; 2013-2022). We assessed adherence to four quality metrics: (1) active surveillance for low-risk PCa; (2) definitive treatment within 12 mo of diagnosis for unfavorable-risk PCa; (3) no staging imaging for favorable-risk PCa; and (4) staging imaging for unfavorable-risk PCa. For χ2 analyses, we combined the three most recent years of data entered by region for each outcome, with adjustment for multiple tests (p = 0.05 ÷ 4 = 0.0125). We also conducted multivariable logistic regression and temporal analyses.

Key findings and limitations: Active surveillance rates for low-risk PCa ranged from 85% in Australia/New Zealand (vs USA: adjusted odds ratio [aOR] 1.042, 95% confidence interval [CI] 0.740-1.520) to 14% in Central Europe (aOR 0.028, 95% CI 0.022-0.036). For patients with unfavorable-risk disease, the highest uptake rate for treatment within 12 mo of diagnosis was in Central Europe (98%; aOR 2.885, 95% CI 1.260-6.603), compared to 70% in Italy (aOR 0.031, 95%CI 0.014-0.072). The proportion of patients with favorable-risk disease who did not undergo imaging ranged from 94% in the USA to 30% in Italy (aOR 0.004, 95% CI 0.002-0.008), while the rate of imaging for unfavorable-risk PCa ranged from 8% in Hong Kong (aOR 65.222, 95% CI 43.676-97.398) to 39% in the USA (all χ2p < 0.0125). Regional temporal trends also varied.

Conclusions and clinical implications: In this international study comparing adherence to quality care metrics for the quality of care for locoregional PCa, we identified regional variance, possibly because of regional differences in cultural attitudes and health care structures. These benchmarks highlight opportunities for interventions to improve adherence to evidence-based guidelines.

Patient summary: Our study shows that adherence to recommended management goals for patients with prostate cancer varies greatly by global region.

背景和目的:遵守指南建议可提高前列腺癌(PCa)患者的治疗质量。我们的目的是评估国际地区对局部区域 PCa 指南的遵循情况:研究队列包括10个国家的Movember TrueNTH全球登记处(n = 62 688;2013-2022年)中确诊为局部区域性PCa的患者。我们评估了四项质量指标的遵守情况:(1) 对低风险 PCa 进行积极监测;(2) 对不利风险 PCa 在诊断后 12 个月内进行明确治疗;(3) 对有利风险 PCa 不进行分期成像;(4) 对不利风险 PCa 进行分期成像。在进行χ2分析时,我们将每个结果按地区输入的最近三年的数据进行了合并,并进行了多重检验调整(P = 0.05 ÷ 4 = 0.0125)。我们还进行了多变量逻辑回归和时间分析:低风险 PCa 的主动监测率从澳大利亚/新西兰的 85%(与美国相比:调整赔率比 [aOR] 1.042,95% 置信区间 [CI] 0.740-1.520] 到中欧的 14%(aOR 0.028,95% CI 0.022-0.036)不等。对于风险较低的患者,在确诊后 12 个月内接受治疗的比例最高的是中欧地区(98%;aOR 2.885,95% CI 1.260-6.603),而意大利为 70%(aOR 0.031,95%CI 0.014-0.072)。未接受影像学检查的良性风险患者比例从美国的 94% 到意大利的 30% 不等(aOR 0.004,95% CI 0.002-0.008),而不良风险 PCa 的影像学检查率从香港的 8% (aOR 65.222,95% CI 43.676-97.398)到美国的 39% 不等(均为 χ2p 结论和临床意义:在这项国际研究中,我们比较了对局部 PCa 优质护理指标的遵守情况,发现了地区差异,这可能是由于文化态度和医疗结构的地区差异造成的。患者总结:我们的研究表明,全球不同地区的前列腺癌患者对推荐管理目标的依从性存在很大差异。
{"title":"International Variations in Adherence to Quality Metrics for Locoregional Prostate Cancer.","authors":"Adam B Weiner, Anissa V Nguyen, Amar U Kishan, Robert E Reiter, Mark S Litwin","doi":"10.1016/j.euo.2024.05.015","DOIUrl":"https://doi.org/10.1016/j.euo.2024.05.015","url":null,"abstract":"<p><strong>Background and objective: </strong>Adherence to guideline recommendations can improve the quality of care for patients with prostate cancer (PCa). Our aim was to assess adherence to guidelines for locoregional PCa by international region.</p><p><strong>Methods: </strong>The study cohort comprised patients diagnosed with locoregional PCa in the 10-country Movember TrueNTH Global Registry (n = 62 688; 2013-2022). We assessed adherence to four quality metrics: (1) active surveillance for low-risk PCa; (2) definitive treatment within 12 mo of diagnosis for unfavorable-risk PCa; (3) no staging imaging for favorable-risk PCa; and (4) staging imaging for unfavorable-risk PCa. For χ<sup>2</sup> analyses, we combined the three most recent years of data entered by region for each outcome, with adjustment for multiple tests (p = 0.05 ÷ 4 = 0.0125). We also conducted multivariable logistic regression and temporal analyses.</p><p><strong>Key findings and limitations: </strong>Active surveillance rates for low-risk PCa ranged from 85% in Australia/New Zealand (vs USA: adjusted odds ratio [aOR] 1.042, 95% confidence interval [CI] 0.740-1.520) to 14% in Central Europe (aOR 0.028, 95% CI 0.022-0.036). For patients with unfavorable-risk disease, the highest uptake rate for treatment within 12 mo of diagnosis was in Central Europe (98%; aOR 2.885, 95% CI 1.260-6.603), compared to 70% in Italy (aOR 0.031, 95%CI 0.014-0.072). The proportion of patients with favorable-risk disease who did not undergo imaging ranged from 94% in the USA to 30% in Italy (aOR 0.004, 95% CI 0.002-0.008), while the rate of imaging for unfavorable-risk PCa ranged from 8% in Hong Kong (aOR 65.222, 95% CI 43.676-97.398) to 39% in the USA (all χ<sup>2</sup>p < 0.0125). Regional temporal trends also varied.</p><p><strong>Conclusions and clinical implications: </strong>In this international study comparing adherence to quality care metrics for the quality of care for locoregional PCa, we identified regional variance, possibly because of regional differences in cultural attitudes and health care structures. These benchmarks highlight opportunities for interventions to improve adherence to evidence-based guidelines.</p><p><strong>Patient summary: </strong>Our study shows that adherence to recommended management goals for patients with prostate cancer varies greatly by global region.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141293233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non-muscle-invasive Bladder Cancer. 治疗非肌层浸润性膀胱癌的新型给药系统和药物治疗方法。
IF 8.2 1区 医学 Q1 ONCOLOGY Pub Date : 2024-06-06 DOI: 10.1016/j.euo.2024.05.012
Félix Guerrero-Ramos, Joost L Boormans, Siamak Daneshmand, Paolo Gontero, Ashish M Kamat, Morgan Rouprêt, Antoni Vilaseca, Shahrokh F Shariat

Background and objective: Therapeutic options for patients with non-muscle-invasive bladder cancer (NMIBC) have traditionally been limited to intravesical immunotherapy or chemotherapy. A considerable number of new options have been investigated in recent years. Our aim was to review the efficacy and toxicity of novel therapeutic options (results already reported or currently under investigation) for patients with NMIBC.

Methods: We assessed the efficacy of various novel therapeutic options by examining key endpoints in diverse settings, including recurrence, progression, overall survival, disease-specific survival, and complete response. We identified the principal advantages and limitations for each option. Safety was predominantly evaluated as the incidence of grade ≥3 adverse events. Our investigation focused on evidence from scientific articles and congress abstracts published in English within the past 5 yr.

Key findings and limitations: To date, pembrolizumab, nadofaragene firadenovec, and the combination of BCG with N-803 have received US Food and Drug administration approval for the treatment of BCG-unresponsive carcinoma in situ of the bladder (with or without papillary tumours). Five phase 3 trials are recruiting BCG-naïve patients with high-risk NMIBC. There is increasing interest in an ablative rather than an adjuvant approach for patients with intermediate-risk NMIBC.

Conclusions and clinical implications: Novel drugs and device-assisted drug delivery systems are on the verge of changing the treatment of NMIBC. Novel intravesical options seem to have the same efficacy with fewer adverse events in comparison to systemic therapies.

Patient summary: We reviewed new therapy options for non-muscle-invasive bladder cancer. Two agents (pembrolizumab and nadofaragene firadenovec) have been approved to date. Ongoing trials are assessing direct delivery of drugs in solution into the bladder. This route seems to have similar efficacy and fewer side effects than intravenous immunotherapy.

背景和目的:非肌层浸润性膀胱癌(NMIBC)患者的治疗方案传统上仅限于膀胱内免疫疗法或化疗。近年来,有相当多的新方案得到了研究。我们的目的是回顾新疗法(已报道或正在研究的结果)对 NMIBC 患者的疗效和毒性:我们评估了各种新型治疗方案的疗效,检查了不同情况下的关键终点,包括复发、病情进展、总生存期、疾病特异性生存期和完全应答。我们确定了每种方案的主要优势和局限性。安全性主要根据≥3级不良事件的发生率进行评估。我们的调查侧重于过去5年内发表的英文科学文章和大会摘要中的证据:迄今为止,pembrolizumab、nadofaragene firadenovec以及卡介苗与N-803的联合用药已获得美国食品和药物管理局批准,用于治疗对卡介苗无反应的膀胱原位癌(伴有或不伴有乳头状肿瘤)。五项 3 期试验正在招募卡介苗无效的高危 NMIBC 患者。对于中度风险的 NMIBC 患者,人们越来越关注消融而非辅助治疗方法:新型药物和设备辅助给药系统即将改变 NMIBC 的治疗方法。与全身疗法相比,新型膀胱内疗法似乎具有相同的疗效,但不良反应较少。患者总结:我们回顾了非肌层浸润性膀胱癌的新疗法选择。迄今为止,已有两种药物(pembrolizumab 和 nadofaragene firadenovec)获得批准。正在进行的试验正在评估将药物溶液直接送入膀胱的方法。与静脉注射免疫疗法相比,这种途径似乎具有相似的疗效和较少的副作用。
{"title":"Novel Delivery Systems and Pharmacotherapeutic Approaches for the Treatment of Non-muscle-invasive Bladder Cancer.","authors":"Félix Guerrero-Ramos, Joost L Boormans, Siamak Daneshmand, Paolo Gontero, Ashish M Kamat, Morgan Rouprêt, Antoni Vilaseca, Shahrokh F Shariat","doi":"10.1016/j.euo.2024.05.012","DOIUrl":"https://doi.org/10.1016/j.euo.2024.05.012","url":null,"abstract":"<p><strong>Background and objective: </strong>Therapeutic options for patients with non-muscle-invasive bladder cancer (NMIBC) have traditionally been limited to intravesical immunotherapy or chemotherapy. A considerable number of new options have been investigated in recent years. Our aim was to review the efficacy and toxicity of novel therapeutic options (results already reported or currently under investigation) for patients with NMIBC.</p><p><strong>Methods: </strong>We assessed the efficacy of various novel therapeutic options by examining key endpoints in diverse settings, including recurrence, progression, overall survival, disease-specific survival, and complete response. We identified the principal advantages and limitations for each option. Safety was predominantly evaluated as the incidence of grade ≥3 adverse events. Our investigation focused on evidence from scientific articles and congress abstracts published in English within the past 5 yr.</p><p><strong>Key findings and limitations: </strong>To date, pembrolizumab, nadofaragene firadenovec, and the combination of BCG with N-803 have received US Food and Drug administration approval for the treatment of BCG-unresponsive carcinoma in situ of the bladder (with or without papillary tumours). Five phase 3 trials are recruiting BCG-naïve patients with high-risk NMIBC. There is increasing interest in an ablative rather than an adjuvant approach for patients with intermediate-risk NMIBC.</p><p><strong>Conclusions and clinical implications: </strong>Novel drugs and device-assisted drug delivery systems are on the verge of changing the treatment of NMIBC. Novel intravesical options seem to have the same efficacy with fewer adverse events in comparison to systemic therapies.</p><p><strong>Patient summary: </strong>We reviewed new therapy options for non-muscle-invasive bladder cancer. Two agents (pembrolizumab and nadofaragene firadenovec) have been approved to date. Ongoing trials are assessing direct delivery of drugs in solution into the bladder. This route seems to have similar efficacy and fewer side effects than intravenous immunotherapy.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141287972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prostate Magnetic Resonance Imaging Using the Prostate Imaging for Recurrence Reporting (PI-RR) Scoring System to Detect Recurrent Prostate Cancer: A Systematic Review and Meta-analysis. 使用前列腺复发成像报告(PI-RR)评分系统检测复发性前列腺癌的前列腺磁共振成像:系统回顾与元分析》。
IF 8.2 1区 医学 Q1 ONCOLOGY Pub Date : 2024-05-31 DOI: 10.1016/j.euo.2024.05.007
Felipe A Mourato, Luiza G Schmitt, Miriana Mariussi, Giovanni Torri, Stephan Altmayer, Francesco Giganti, Jorge Abreu-Gomez, Nathan Perlis, Alejandro Berlin, Sangeet Ghai, Masoom A Haider, Adriano B Dias

Background and objective: Prostate Imaging for Recurrence Reporting (PI-RR) was introduced in 2021 to standardize the interpretation and reporting of multiparametric magnetic resonance imaging (MRI) for prostate cancer following whole-gland treatment. The system scores image on a scale from 1 to 5 and has shown promising results in single-center studies. The aim of our systematic review and meta-analysis was to assess the diagnostic performance of the PI-RR system in predicting the likelihood of local recurrence after whole-gland treatment.

Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for diagnostic test accuracy were followed. Relevant databases were searched up to December 2023. Primary studies met the eligibility criteria if they reported MRI diagnostic performance in prostate cancer recurrence using PI-RR. Diagnostic performance for MRI was assessed using two different cutoff points (≥3 or ≥4 for positivity according to the PI-RR system). A meta-analysis with a random-effects model was used to estimate pooled sensitivity and specificity values.

Key findings and limitations: Sixteen articles were identified for full-text reading, of which six were considered eligible, involving a total of 467 patients. Using a cutoff of PI-RR ≥3 (4 studies) for recurrent disease, the sensitivity was 77.8% (95% confidence interval [CI] 69.9-84.1%) and the specificity was 80.2% (95% CI 58.2-92.2%). Using a cutoff of PI-RR ≥4 (4 studies), the sensitivity was 61.9% (95% CI 35.6-82.7%) and the specificity was 86.6% (95% CI 75.1-93.3%). Overall, the inter-rater agreement varied from fair to excellent.

Conclusions and clinical implications: PI-RR is accurate in detecting local recurrence after whole-gland treatment for prostate cancer and shows fair-to-good to excellent inter-reader agreement. Overall, a PI-RR cutoff of ≥3 showed high sensitivity and specificity.

Patient summary: We reviewed studies that reported on how good MRI scans using a scoring system called PI-RR were in detecting recurrence of prostate cancer. We found that this system shows good performance, with fair to excellent agreement between different radiologists.

背景和目的:前列腺复发成像报告(PI-RR)于 2021 年推出,旨在规范前列腺癌全腺体治疗后多参数磁共振成像(MRI)的解释和报告。该系统对图像进行 1 到 5 级评分,在单中心研究中显示出良好的效果。我们的系统综述和荟萃分析旨在评估 PI-RR 系统在预测全腺治疗后局部复发可能性方面的诊断性能:方法:遵循系统综述和荟萃分析首选报告项目(PRISMA)指南中关于诊断测试准确性的规定。检索了截至 2023 年 12 月的相关数据库。如果主要研究报告了使用PI-RR对前列腺癌复发的MRI诊断性能,则符合资格标准。磁共振成像的诊断性能采用两种不同的截断点(根据PI-RR系统,阳性≥3或≥4)进行评估。采用随机效应模型进行荟萃分析,以估算汇总的敏感性和特异性值:对16篇文章进行了全文阅读,其中6篇符合条件,共涉及467名患者。以 PI-RR ≥3(4 项研究)为复发疾病的临界值,敏感性为 77.8%(95% 置信区间 [CI] 69.9-84.1%),特异性为 80.2%(95% 置信区间 [CI] 58.2-92.2%)。以 PI-RR≥4 为临界值(4 项研究),灵敏度为 61.9%(95% CI 35.6-82.7%),特异性为 86.6%(95% CI 75.1-93.3%)。总体而言,评分者之间的一致性从一般到优秀不等:结论和临床意义:PI-RR 可准确检测前列腺癌全腺治疗后的局部复发,读片者之间的一致性从一般到良好再到优秀不等。总体而言,PI-RR 临界值≥3 显示出较高的灵敏度和特异性。患者总结:我们回顾了使用一种名为 PI-RR 的评分系统检测前列腺癌复发的 MRI 扫描效果如何的研究报告。我们发现,该系统性能良好,不同放射科医生之间的一致性从一般到优秀不等。
{"title":"Prostate Magnetic Resonance Imaging Using the Prostate Imaging for Recurrence Reporting (PI-RR) Scoring System to Detect Recurrent Prostate Cancer: A Systematic Review and Meta-analysis.","authors":"Felipe A Mourato, Luiza G Schmitt, Miriana Mariussi, Giovanni Torri, Stephan Altmayer, Francesco Giganti, Jorge Abreu-Gomez, Nathan Perlis, Alejandro Berlin, Sangeet Ghai, Masoom A Haider, Adriano B Dias","doi":"10.1016/j.euo.2024.05.007","DOIUrl":"https://doi.org/10.1016/j.euo.2024.05.007","url":null,"abstract":"<p><strong>Background and objective: </strong>Prostate Imaging for Recurrence Reporting (PI-RR) was introduced in 2021 to standardize the interpretation and reporting of multiparametric magnetic resonance imaging (MRI) for prostate cancer following whole-gland treatment. The system scores image on a scale from 1 to 5 and has shown promising results in single-center studies. The aim of our systematic review and meta-analysis was to assess the diagnostic performance of the PI-RR system in predicting the likelihood of local recurrence after whole-gland treatment.</p><p><strong>Methods: </strong>The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for diagnostic test accuracy were followed. Relevant databases were searched up to December 2023. Primary studies met the eligibility criteria if they reported MRI diagnostic performance in prostate cancer recurrence using PI-RR. Diagnostic performance for MRI was assessed using two different cutoff points (≥3 or ≥4 for positivity according to the PI-RR system). A meta-analysis with a random-effects model was used to estimate pooled sensitivity and specificity values.</p><p><strong>Key findings and limitations: </strong>Sixteen articles were identified for full-text reading, of which six were considered eligible, involving a total of 467 patients. Using a cutoff of PI-RR ≥3 (4 studies) for recurrent disease, the sensitivity was 77.8% (95% confidence interval [CI] 69.9-84.1%) and the specificity was 80.2% (95% CI 58.2-92.2%). Using a cutoff of PI-RR ≥4 (4 studies), the sensitivity was 61.9% (95% CI 35.6-82.7%) and the specificity was 86.6% (95% CI 75.1-93.3%). Overall, the inter-rater agreement varied from fair to excellent.</p><p><strong>Conclusions and clinical implications: </strong>PI-RR is accurate in detecting local recurrence after whole-gland treatment for prostate cancer and shows fair-to-good to excellent inter-reader agreement. Overall, a PI-RR cutoff of ≥3 showed high sensitivity and specificity.</p><p><strong>Patient summary: </strong>We reviewed studies that reported on how good MRI scans using a scoring system called PI-RR were in detecting recurrence of prostate cancer. We found that this system shows good performance, with fair to excellent agreement between different radiologists.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141186285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Circulating Biomarkers Predictive of Treatment Response in Patients with Hormone-sensitive or Castration-resistant Metastatic Prostate Cancer: A Systematic Review. 预测激素敏感或阉割耐药转移性前列腺癌患者治疗反应的循环生物标志物:系统回顾
IF 8.2 1区 医学 Q1 ONCOLOGY Pub Date : 2024-05-31 DOI: 10.1016/j.euo.2024.05.003
Michael Baboudjian, Arthur Peyrottes, Charles Dariane, Gaëlle Fromont, Jérôme Alexandre Denis, Gaëlle Fiard, Diana Kassab, Sylvain Ladoire, Jacqueline Lehmann-Che, Guillaume Ploussard, Morgan Rouprêt, Philippe Barthélémy, Guilhem Roubaud, Pierre-Jean Lamy

Background and objective: Metastatic prostate cancer (mPCa) harbors genomic alterations that may predict targeted therapy efficacy. These alterations can be identified not only in tissue but also directly in biologic fluids (ie, liquid biopsies), mainly blood. Liquid biopsies may represent a safer and less invasive alternative for monitoring patients treated for mPCa. Current research focuses on the description and validation of novel predictive biomarkers to improve precision medicine in mPCa. Our aim was to systematically review the current evidence on liquid biopsy biomarkers for predicting treatment response in mPCa.

Methods: We systematically searched Medline, Web of Science, and evidence-based websites for publications on circulating biomarkers in mPCa between March 2013 and February 2024 for review. Endpoints were: prediction of overall survival, biochemical or radiographic progression-free survival after treatment (chemotherapy, androgen deprivation therapy, androgen receptor pathway inhibitors [ARPIs], immunotherapy, or PARP inhibitors [PARPIs]). For each biomarker, the level of evidence (LOE) for clinical validity was attributed: LOE IA and IB, high level of evidence; LOE IIB and IIC, intermediate level; and LOE IIIC and LOE IV-VD, weak level.

Key findings and limitations: The predictive value of each biomarker for the response to several therapies was evaluated in both metastatic hormone-sensitive (mHSPC) and castration-resistant prostate cancer (mCRPC). In patients with mCRPC, BRCA1/2 or ATM mutations predicted response to ARPIs (LOE IB) and PARPIs (LOE IIB), while AR-V7 transcripts or AR-V7 protein levels in circulating tumor cells (CTCs) predicted response to ARPIs and taxanes (LOE IB). CTC quantification predicted response to cabazitaxel, abiraterone, and radium-223 (LOE IIB), while TP53 alterations predicted response to 177Lu prostate-specific membrane antigen radioligand treatment (LOE IIB). AR copy number in circulating tumor DNA before the first treatment line and before subsequent lines predicted response to docetaxel, cabazitaxel, and ARPIs (LOE IIB). In mHSPC, DNA damage in lymphocytes was predictive of the response to radium-223 (LOE IIB).

Conclusions and clinical implications: BRCA1/2, ATM, and AR alterations detected in liquid biopsies may help clinicians in management of patients with mPCa. The other circulating biomarkers did not reach the LOE required for routine clinical use and should be validated in prospective independent studies.

Patient summary: We reviewed studies assessing the value of biomarkers in blood or urine for management of metastatic prostate cancer. The evidence indicates that some biomarkers could help in selecting patients eligible for specific treatments.

背景和目的:转移性前列腺癌(mPCa)的基因组改变可预测靶向治疗的疗效。这些改变不仅可在组织中发现,还可直接在生物液体(即液体活检)(主要是血液)中发现。液体活检可能是监测接受 mPCa 治疗的患者的一种更安全、创伤更小的替代方法。目前的研究重点是描述和验证新型预测性生物标记物,以改善对mPCa的精准医疗。我们的目的是系统回顾目前有关预测 mPCa 治疗反应的液体生物标记物的证据:我们系统地检索了 Medline、Web of Science 和循证网站上 2013 年 3 月至 2024 年 2 月期间有关 mPCa 循环生物标志物的出版物,以进行回顾。研究终点为:预测治疗(化疗、雄激素剥夺疗法、雄激素受体通路抑制剂[ARPIs]、免疫疗法或PARP抑制剂[PARPIs])后的总生存期、生化或放射学无进展生存期。对于每种生物标记物,临床有效性的证据级别(LOE)均已确定:LOE IA和IB为高证据等级;LOE IIB和IIC为中等证据等级;LOE IIIC和LOE IV-VD为弱证据等级:在转移性激素敏感型前列腺癌(mHSPC)和阉割耐药型前列腺癌(mCRPC)中评估了每种生物标志物对几种疗法反应的预测价值。在mCRPC患者中,BRCA1/2或ATM突变可预测对ARPIs(LOE IB)和PARPIs(LOE IIB)的反应,而循环肿瘤细胞(CTC)中的AR-V7转录物或AR-V7蛋白水平可预测对ARPIs和紫杉类药物(LOE IB)的反应。CTC定量可预测对卡巴他赛、阿比特龙和镭-223的反应(LOE IIB),而TP53改变可预测对177Lu前列腺特异性膜抗原放射性配体治疗的反应(LOE IIB)。第一线治疗前和后续治疗前循环肿瘤DNA中的AR拷贝数可预测对多西他赛、卡巴他赛和ARPIs的反应(LOE IIB)。在mHSPC中,淋巴细胞中的DNA损伤可预测对镭-223的反应(LOE IIB):结论与临床意义:液体活检中检测到的BRCA1/2、ATM和AR改变可帮助临床医生管理mPCa患者。其他循环生物标志物未达到常规临床应用所需的 LOE,应在前瞻性独立研究中进行验证。患者总结:我们回顾了评估血液或尿液中生物标志物对转移性前列腺癌治疗价值的研究。证据表明,某些生物标志物有助于选择符合特定治疗条件的患者。
{"title":"Circulating Biomarkers Predictive of Treatment Response in Patients with Hormone-sensitive or Castration-resistant Metastatic Prostate Cancer: A Systematic Review.","authors":"Michael Baboudjian, Arthur Peyrottes, Charles Dariane, Gaëlle Fromont, Jérôme Alexandre Denis, Gaëlle Fiard, Diana Kassab, Sylvain Ladoire, Jacqueline Lehmann-Che, Guillaume Ploussard, Morgan Rouprêt, Philippe Barthélémy, Guilhem Roubaud, Pierre-Jean Lamy","doi":"10.1016/j.euo.2024.05.003","DOIUrl":"https://doi.org/10.1016/j.euo.2024.05.003","url":null,"abstract":"<p><strong>Background and objective: </strong>Metastatic prostate cancer (mPCa) harbors genomic alterations that may predict targeted therapy efficacy. These alterations can be identified not only in tissue but also directly in biologic fluids (ie, liquid biopsies), mainly blood. Liquid biopsies may represent a safer and less invasive alternative for monitoring patients treated for mPCa. Current research focuses on the description and validation of novel predictive biomarkers to improve precision medicine in mPCa. Our aim was to systematically review the current evidence on liquid biopsy biomarkers for predicting treatment response in mPCa.</p><p><strong>Methods: </strong>We systematically searched Medline, Web of Science, and evidence-based websites for publications on circulating biomarkers in mPCa between March 2013 and February 2024 for review. Endpoints were: prediction of overall survival, biochemical or radiographic progression-free survival after treatment (chemotherapy, androgen deprivation therapy, androgen receptor pathway inhibitors [ARPIs], immunotherapy, or PARP inhibitors [PARPIs]). For each biomarker, the level of evidence (LOE) for clinical validity was attributed: LOE IA and IB, high level of evidence; LOE IIB and IIC, intermediate level; and LOE IIIC and LOE IV-VD, weak level.</p><p><strong>Key findings and limitations: </strong>The predictive value of each biomarker for the response to several therapies was evaluated in both metastatic hormone-sensitive (mHSPC) and castration-resistant prostate cancer (mCRPC). In patients with mCRPC, BRCA1/2 or ATM mutations predicted response to ARPIs (LOE IB) and PARPIs (LOE IIB), while AR-V7 transcripts or AR-V7 protein levels in circulating tumor cells (CTCs) predicted response to ARPIs and taxanes (LOE IB). CTC quantification predicted response to cabazitaxel, abiraterone, and radium-223 (LOE IIB), while TP53 alterations predicted response to <sup>177</sup>Lu prostate-specific membrane antigen radioligand treatment (LOE IIB). AR copy number in circulating tumor DNA before the first treatment line and before subsequent lines predicted response to docetaxel, cabazitaxel, and ARPIs (LOE IIB). In mHSPC, DNA damage in lymphocytes was predictive of the response to radium-223 (LOE IIB).</p><p><strong>Conclusions and clinical implications: </strong>BRCA1/2, ATM, and AR alterations detected in liquid biopsies may help clinicians in management of patients with mPCa. The other circulating biomarkers did not reach the LOE required for routine clinical use and should be validated in prospective independent studies.</p><p><strong>Patient summary: </strong>We reviewed studies assessing the value of biomarkers in blood or urine for management of metastatic prostate cancer. The evidence indicates that some biomarkers could help in selecting patients eligible for specific treatments.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141186283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient-reported Outcome Measures and Experience Measures After Active Surveillance Versus Radiation Therapy Versus Radical Prostatectomy for Prostate Cancer: A Systematic Review of Prospective Comparative Studies. 前列腺癌主动监测、放射治疗和根治性前列腺切除术后的患者报告结果测量和体验测量:前瞻性比较研究的系统回顾。
IF 8.2 1区 医学 Q1 ONCOLOGY Pub Date : 2024-05-29 DOI: 10.1016/j.euo.2024.05.008
Andrea Alberti, Rossella Nicoletti, Daniele Castellani, Yuhong Yuan, Martina Maggi, Edoardo Dibilio, Giulio Raffaele Resta, Pantelis Makrides, Francesco Sessa, Arcangelo Sebastianelli, Sergio Serni, Mauro Gacci, Cosimo De Nunzio, Jeremy Y C Teoh, Riccardo Campi

Background and objective: Current management options for localized prostate cancer (PCa) include radical prostatectomy (RP), radiotherapy (RT), and active surveillance (AS). Despite comparable oncological outcomes, there is still lack of evidence on their comparative effectiveness in terms of patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs). We conducted a systematic review of studies comparing PROMs and PREMs after all recommended management options for localized PCa (RP, RT, AS).

Methods: A literature search was performed in the MEDLINE, EMBASE, and Cochrane CENTRAL databases in accordance with recommendations from the European Association of Urology Guidelines Office and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. All prospective clinical trials reporting PROMs and/or PREMs for comparisons of RP versus RT versus AS were included. A narrative synthesis was used to summarize the review findings. No quantitative synthesis was performed because of the heterogeneity and limitations of the studies available.

Key findings and limitations: Our findings reveal that RP mostly affects urinary continence and sexual function, with better results for voiding symptoms in comparison to other treatments. RT was associated with greater impairment of bowel function and voiding symptoms. None of the treatments had a significant impact on mental or physical quality of life. Only a few studies reported PREMs, with a high rate of decision regret for all modalities (up to 23%).

Conclusions and clinical implications: All recommended treatments for localized PCa have an impact on PROMs and PREMs, but for different domains and with differing severity. We found significant heterogeneity in PROM collection, so standardization in real-world practice and clinical trials is warranted. Only a few studies have reported PREMs, highlighting an unmet need that should be explored in future studies.

Patient summary: We reviewed differences in patient reports of their outcomes and experiences after surgical prostate removal, radiotherapy, or active surveillance for prostate cancer. We found differences in the effects on urinary, bowel, and sexual functions among the treatments, but no difference for mental or physical quality of life. Our results can help doctors and prostate cancer patients in shared decision-making.

背景和目的:目前治疗局部前列腺癌(PCa)的方法包括根治性前列腺切除术(RP)、放射治疗(RT)和主动监测(AS)。尽管它们的肿瘤治疗效果相当,但在患者报告的结果测量指标(PROMs)和患者报告的体验测量指标(PREMs)方面,仍缺乏有关其比较效果的证据。我们对所有推荐的局部 PCa 治疗方案(RP、RT、AS)后的 PROMs 和 PREMs 比较研究进行了系统性回顾:根据欧洲泌尿外科协会指南办公室的建议和《系统综述和元分析首选报告项目》声明,我们在 MEDLINE、EMBASE 和 Cochrane CENTRAL 数据库中进行了文献检索。所有报告 PROMs 和/或 PREMs 的前瞻性临床试验均纳入 RP 与 RT 与 AS 的比较。采用叙事综合法对综述结果进行总结。由于现有研究的异质性和局限性,未进行定量综合:我们的研究结果表明,RP主要影响尿失禁和性功能,与其他治疗方法相比,RP对排尿症状的效果更好。RT对排便功能和排尿症状的影响更大。所有治疗方法都不会对精神或身体的生活质量产生重大影响。只有少数研究报告了PREMs,所有方式的决策后悔率都很高(高达23%):结论和临床意义:所有推荐的局部 PCa 治疗方法都会对 PROMs 和 PREMs 产生影响,但影响的领域和严重程度各不相同。我们发现PROM的收集存在很大的异质性,因此需要在实际实践和临床试验中进行标准化。患者摘要:我们回顾了前列腺癌手术切除、放疗或主动监测后患者对其结果和经历的报告差异。我们发现不同治疗方法对排尿、排便和性功能的影响存在差异,但对精神或身体生活质量的影响没有差异。我们的研究结果有助于医生和前列腺癌患者共同决策。
{"title":"Patient-reported Outcome Measures and Experience Measures After Active Surveillance Versus Radiation Therapy Versus Radical Prostatectomy for Prostate Cancer: A Systematic Review of Prospective Comparative Studies.","authors":"Andrea Alberti, Rossella Nicoletti, Daniele Castellani, Yuhong Yuan, Martina Maggi, Edoardo Dibilio, Giulio Raffaele Resta, Pantelis Makrides, Francesco Sessa, Arcangelo Sebastianelli, Sergio Serni, Mauro Gacci, Cosimo De Nunzio, Jeremy Y C Teoh, Riccardo Campi","doi":"10.1016/j.euo.2024.05.008","DOIUrl":"https://doi.org/10.1016/j.euo.2024.05.008","url":null,"abstract":"<p><strong>Background and objective: </strong>Current management options for localized prostate cancer (PCa) include radical prostatectomy (RP), radiotherapy (RT), and active surveillance (AS). Despite comparable oncological outcomes, there is still lack of evidence on their comparative effectiveness in terms of patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMs). We conducted a systematic review of studies comparing PROMs and PREMs after all recommended management options for localized PCa (RP, RT, AS).</p><p><strong>Methods: </strong>A literature search was performed in the MEDLINE, EMBASE, and Cochrane CENTRAL databases in accordance with recommendations from the European Association of Urology Guidelines Office and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. All prospective clinical trials reporting PROMs and/or PREMs for comparisons of RP versus RT versus AS were included. A narrative synthesis was used to summarize the review findings. No quantitative synthesis was performed because of the heterogeneity and limitations of the studies available.</p><p><strong>Key findings and limitations: </strong>Our findings reveal that RP mostly affects urinary continence and sexual function, with better results for voiding symptoms in comparison to other treatments. RT was associated with greater impairment of bowel function and voiding symptoms. None of the treatments had a significant impact on mental or physical quality of life. Only a few studies reported PREMs, with a high rate of decision regret for all modalities (up to 23%).</p><p><strong>Conclusions and clinical implications: </strong>All recommended treatments for localized PCa have an impact on PROMs and PREMs, but for different domains and with differing severity. We found significant heterogeneity in PROM collection, so standardization in real-world practice and clinical trials is warranted. Only a few studies have reported PREMs, highlighting an unmet need that should be explored in future studies.</p><p><strong>Patient summary: </strong>We reviewed differences in patient reports of their outcomes and experiences after surgical prostate removal, radiotherapy, or active surveillance for prostate cancer. We found differences in the effects on urinary, bowel, and sexual functions among the treatments, but no difference for mental or physical quality of life. Our results can help doctors and prostate cancer patients in shared decision-making.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141179120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hematuria Cancer Risk Score with Ultrasound Informs Cystoscopy Use in Patients with Hematuria. 利用超声波进行血尿癌症风险评分,为血尿患者进行膀胱镜检查提供依据。
IF 8.2 1区 医学 Q1 ONCOLOGY Pub Date : 2024-05-28 DOI: 10.1016/j.euo.2024.05.005
Wei Shen Tan, Amar Ahmad, Yin Zhou, Arjun Nathan, Ayodeji Ogunbo, Olayinka Gbolahan, Neha Kallam, Rebecca Smith, Maen Khalifeh, Wei Phin Tan, Daniel Cohen, Dimitrios Volanis, Fiona M Walter, Peter Sasieni, Ashish M Kamat, John D Kelly

Background: Hematuria is a cardinal symptom of urinary tract cancer and would require further investigations.

Objective: To determine the ability of renal bladder ultrasound (RBUS) with the Hematuria Cancer Risk Score (HCRS) to inform cystoscopy use in patients with hematuria.

Design, setting, and participants: The development cohort comprised 1984 patients with hematuria from 40 UK hospitals (DETECT 1; ClinicalTrials.gov: NCT02676180) who received RBUS. An independent validation cohort comprised 500 consecutive patients referred to secondary care for a suspicion of bladder cancer.

Outcome measurements and statistical analysis: Sensitivity and true negative of the HCRS and RBUS were assessed.

Results and limitations: A total of 134 (7%) and 36 (8%) patients in the development and validation cohorts, respectively, had a diagnosis of urinary tract cancer. Validation of the HCRS achieves good discrimination with an area under the receiver operating characteristic curve of 0.727 (95% confidence interval 0.648-0.800) in the validation cohort with sensitivity of 95% for the identification of cancer. Utilizing the cutoff of 4.500 derived from the HCRS in combination with RBUS in the development cohort, 680 (34%) patients would have been spared cystoscopy at the cost of missing a G1 Ta bladder cancer and a urinary tract cancer patient, while 117 (25%) patients would have avoided cystoscopy at the cost of missing a single patient of G1 Ta bladder cancer with sensitivity for the identification of cancer of 97% in the validation cohort.

Conclusions: The HCRS with RBUS offers good discriminatory ability in identifying patients who would benefit from cystoscopy, sparing selected patient cohorts from an invasive procedure.

Patient summary: The hematuria cancer risk score with renal bladder ultrasound allows for the triage of patients with hematuria who would benefit from visual examination of the bladder (cystoscopy). This resulted in 25% of patients safely omitting cystoscopy, which is an invasive procedure, and would lead to health care cost savings.

背景:血尿是尿路癌的主要症状,需要进一步检查:血尿是尿路癌的主要症状,需要进一步检查:目的:确定肾膀胱超声(RBUS)和血尿癌症风险评分(HCRS)为血尿患者进行膀胱镜检查提供依据的能力:开发队列包括来自英国 40 家医院的 1984 名接受 RBUS 检查的血尿患者(DETECT 1;ClinicalTrials.gov:NCT02676180)。一个独立的验证队列包括500名因怀疑患有膀胱癌而转诊至二级医疗机构的连续患者:结果测量和统计分析:评估了 HCRS 和 RBUS 的敏感性和真阴性:在开发队列和验证队列中,分别有 134 名(7%)和 36 名(8%)患者确诊为尿路癌。HCRS 的验证取得了良好的鉴别效果,验证队列的接收器操作特征曲线下面积为 0.727(95% 置信区间为 0.648-0.800),癌症鉴别灵敏度为 95%。如果在开发队列中将 HCRS 与 RBUS 结合使用得出的临界值定为 4.500,则有 680 名(34%)患者可免于膀胱镜检查,但代价是漏诊一名 G1 Ta 膀胱癌和一名尿路癌患者,而有 117 名(25%)患者可免于膀胱镜检查,但代价是漏诊一名 G1 Ta 膀胱癌患者,验证队列中癌症鉴定的灵敏度为 97%:患者总结:血尿癌症风险评分与肾脏膀胱超声相结合,可对血尿患者进行分流,使其受益于膀胱直观检查(膀胱镜检查)。这使得25%的患者安全地省去了膀胱镜检查这一侵入性手术,从而节省了医疗成本。
{"title":"Hematuria Cancer Risk Score with Ultrasound Informs Cystoscopy Use in Patients with Hematuria.","authors":"Wei Shen Tan, Amar Ahmad, Yin Zhou, Arjun Nathan, Ayodeji Ogunbo, Olayinka Gbolahan, Neha Kallam, Rebecca Smith, Maen Khalifeh, Wei Phin Tan, Daniel Cohen, Dimitrios Volanis, Fiona M Walter, Peter Sasieni, Ashish M Kamat, John D Kelly","doi":"10.1016/j.euo.2024.05.005","DOIUrl":"https://doi.org/10.1016/j.euo.2024.05.005","url":null,"abstract":"<p><strong>Background: </strong>Hematuria is a cardinal symptom of urinary tract cancer and would require further investigations.</p><p><strong>Objective: </strong>To determine the ability of renal bladder ultrasound (RBUS) with the Hematuria Cancer Risk Score (HCRS) to inform cystoscopy use in patients with hematuria.</p><p><strong>Design, setting, and participants: </strong>The development cohort comprised 1984 patients with hematuria from 40 UK hospitals (DETECT 1; ClinicalTrials.gov: NCT02676180) who received RBUS. An independent validation cohort comprised 500 consecutive patients referred to secondary care for a suspicion of bladder cancer.</p><p><strong>Outcome measurements and statistical analysis: </strong>Sensitivity and true negative of the HCRS and RBUS were assessed.</p><p><strong>Results and limitations: </strong>A total of 134 (7%) and 36 (8%) patients in the development and validation cohorts, respectively, had a diagnosis of urinary tract cancer. Validation of the HCRS achieves good discrimination with an area under the receiver operating characteristic curve of 0.727 (95% confidence interval 0.648-0.800) in the validation cohort with sensitivity of 95% for the identification of cancer. Utilizing the cutoff of 4.500 derived from the HCRS in combination with RBUS in the development cohort, 680 (34%) patients would have been spared cystoscopy at the cost of missing a G1 Ta bladder cancer and a urinary tract cancer patient, while 117 (25%) patients would have avoided cystoscopy at the cost of missing a single patient of G1 Ta bladder cancer with sensitivity for the identification of cancer of 97% in the validation cohort.</p><p><strong>Conclusions: </strong>The HCRS with RBUS offers good discriminatory ability in identifying patients who would benefit from cystoscopy, sparing selected patient cohorts from an invasive procedure.</p><p><strong>Patient summary: </strong>The hematuria cancer risk score with renal bladder ultrasound allows for the triage of patients with hematuria who would benefit from visual examination of the bladder (cystoscopy). This resulted in 25% of patients safely omitting cystoscopy, which is an invasive procedure, and would lead to health care cost savings.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141175240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and Efficacy of Immediate Hyperthermic Intravesical Chemotherapy Following Transurethral Resection of Bladder Tumour (I-HIVEC). 经尿道膀胱肿瘤切除术后立即热疗膀胱内化疗(I-HIVEC)的安全性和有效性
IF 8.2 1区 医学 Q1 ONCOLOGY Pub Date : 2024-05-27 DOI: 10.1016/j.euo.2024.05.006
Chris Ho-Ming Wong, Ivan Ching-Ho Ko, David Ka-Wai Leung, Steffi Kar-Kei Yuen, Samson Yun-Sang Chan, Samuel Chi-Hang Yee, Peter Ka-Fung Chiu, Chi-Fai Ng, Jeremy Yuen-Chun Teoh

The recurrence rate following endoscopic treatment of non-muscle-invasive bladder cancer (NMIBC) remains high. Standard treatment includes intravesical instillation of chemotoxic agents such as mitomycin C (MMC) to reduce recurrence. It is postulated that upfront administration of hyperthermic intravesical MMC (HIVEC) immediately after transurethral resection of bladder tumour (TURBT) may enhance its efficacy, but evidence from human trials is scant. This pilot study explored the safety of immediate intravesical MMC instillation following TURBT using a conductive HIVEC system (Combat BRS). Patients diagnosed with papillary bladder tumours scheduled for TURBT were recruited. Among 29 patients treated with HIVEC, there was minimal additional postoperative morbidity. The majority (79.3%) were discharged after a hospital stay of 1 d, and no patient required bladder irrigation. There were six grade I-II adverse events (20.7%) and one grade III event (3.4%). No recurrences were observed within 3 mo, and the 12-mo recurrence rate was 4.5%. The study findings demonstrate that immediate HIVEC MMC instillation following TURBT is safe. Further research is needed to assess long-term efficacy in comparison to standard cold MMC. PATIENT SUMMARY: Non-muscle-invasive bladder cancer is treated with tumour removal via a telescope inserted into the bladder through the urethra (called TURBT). We tested the safety of treating the bladder with a warm solution of a chemotherapy drug (mitomycin C) immediately after TURBT, as this may prevent tumour recurrence. The treatment was safe and well tolerated. Further trials are needed with more patients and longer follow-up to confirm the results.

非肌层浸润性膀胱癌(NMIBC)经内窥镜治疗后的复发率仍然很高。标准治疗包括膀胱内灌注丝裂霉素 C(MMC)等化学毒剂,以降低复发率。据推测,在经尿道膀胱肿瘤切除术(TURBT)后立即先期给予膀胱内热疗 MMC(HIVEC)可能会提高疗效,但来自人体试验的证据并不多。这项试验性研究探讨了经尿道膀胱肿瘤切除术后使用传导式 HIVEC 系统(Combat BRS)立即进行膀胱内 MMC 灌注的安全性。研究招募了被诊断为乳头状膀胱肿瘤并计划进行 TURBT 的患者。在接受 HIVEC 治疗的 29 名患者中,术后的额外发病率极低。大多数患者(79.3%)住院1天后即可出院,没有患者需要进行膀胱冲洗。共发生六次 I-II 级不良事件(20.7%)和一次 III 级不良事件(3.4%)。3 个月内未发现复发,12 个月内复发率为 4.5%。研究结果表明,TURBT术后立即灌注HIVEC MMC是安全的。与标准的冷 MMC 相比,还需要进一步的研究来评估其长期疗效。患者摘要:治疗非肌层浸润性膀胱癌的方法是通过尿道插入膀胱的望远镜切除肿瘤(称为 TURBT)。我们测试了在 TURBT 术后立即用一种化疗药物(丝裂霉素 C)的温溶液治疗膀胱的安全性,因为这可以防止肿瘤复发。治疗安全且耐受性良好。我们需要对更多患者和更长时间的随访进行进一步试验,以确认结果。
{"title":"Safety and Efficacy of Immediate Hyperthermic Intravesical Chemotherapy Following Transurethral Resection of Bladder Tumour (I-HIVEC).","authors":"Chris Ho-Ming Wong, Ivan Ching-Ho Ko, David Ka-Wai Leung, Steffi Kar-Kei Yuen, Samson Yun-Sang Chan, Samuel Chi-Hang Yee, Peter Ka-Fung Chiu, Chi-Fai Ng, Jeremy Yuen-Chun Teoh","doi":"10.1016/j.euo.2024.05.006","DOIUrl":"https://doi.org/10.1016/j.euo.2024.05.006","url":null,"abstract":"<p><p>The recurrence rate following endoscopic treatment of non-muscle-invasive bladder cancer (NMIBC) remains high. Standard treatment includes intravesical instillation of chemotoxic agents such as mitomycin C (MMC) to reduce recurrence. It is postulated that upfront administration of hyperthermic intravesical MMC (HIVEC) immediately after transurethral resection of bladder tumour (TURBT) may enhance its efficacy, but evidence from human trials is scant. This pilot study explored the safety of immediate intravesical MMC instillation following TURBT using a conductive HIVEC system (Combat BRS). Patients diagnosed with papillary bladder tumours scheduled for TURBT were recruited. Among 29 patients treated with HIVEC, there was minimal additional postoperative morbidity. The majority (79.3%) were discharged after a hospital stay of 1 d, and no patient required bladder irrigation. There were six grade I-II adverse events (20.7%) and one grade III event (3.4%). No recurrences were observed within 3 mo, and the 12-mo recurrence rate was 4.5%. The study findings demonstrate that immediate HIVEC MMC instillation following TURBT is safe. Further research is needed to assess long-term efficacy in comparison to standard cold MMC. PATIENT SUMMARY: Non-muscle-invasive bladder cancer is treated with tumour removal via a telescope inserted into the bladder through the urethra (called TURBT). We tested the safety of treating the bladder with a warm solution of a chemotherapy drug (mitomycin C) immediately after TURBT, as this may prevent tumour recurrence. The treatment was safe and well tolerated. Further trials are needed with more patients and longer follow-up to confirm the results.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141160094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness and Cost-effectiveness of Artificial Intelligence-assisted Pathology for Prostate Cancer Diagnosis in Sweden: A Microsimulation Study. 瑞典人工智能辅助病理诊断前列腺癌的有效性和成本效益:微观模拟研究》。
IF 8.2 1区 医学 Q1 ONCOLOGY Pub Date : 2024-05-23 DOI: 10.1016/j.euo.2024.05.004
Xiaoyang Du, Shuang Hao, Henrik Olsson, Kimmo Kartasalo, Nita Mulliqi, Balram Rai, Dominik Menges, Emelie Heintz, Lars Egevad, Martin Eklund, Mark Clements

Background and objective: Image-based artificial intelligence (AI) methods have shown high accuracy in prostate cancer (PCa) detection. Their impact on patient outcomes and cost effectiveness in comparison to human pathologists remains unknown. Our aim was to evaluate the effectiveness and cost-effectiveness of AI-assisted pathology for PCa diagnosis in Sweden.

Methods: We modeled quadrennial prostate-specific antigen (PSA) screening for men between the ages of 50 and 74 yr over a lifetime horizon using a health care perspective. Men with PSA ≥3 ng/ml were referred for standard biopsy (SBx), for which cores were either examined via AI followed by a pathologist for AI-labeled positive cores, or a pathologist alone. The AI performance characteristics were estimated using an internal STHLM3 validation data set. Outcome measures included the number of tests, PCa incidence and mortality, overdiagnosis, quality-adjusted life years (QALYs), and the potential reduction in pathologist-evaluated biopsy cores if AI were used. Cost-effectiveness was assessed using the incremental cost-effectiveness ratio.

Key findings and limitations: In comparison to a pathologist alone, the AI-assisted workflow increased the number of PSA tests, SBx procedures, and PCa deaths by ≤0.03%, and slightly reduced PCa incidence and overdiagnosis. AI would reduce the proportion of biopsy cores evaluated by a pathologist by 80%. At a cost of €10 per case, the AI-assisted workflow would cost less and result in <0.001% lower QALYs in comparison to a pathologist alone. The results were sensitive to the AI cost.

Conclusions and clinical implications: According to our model, AI-assisted pathology would significantly decrease the workload of pathologists, would not affect patient quality of life, and would yield cost savings in Sweden when compared to a human pathologist alone.

Patient summary: We compared outcomes for prostate cancer patients and relevant costs for two methods of assessing prostate biopsies in Sweden: (1) artificial intelligence (AI) technology and review of positive biopsies by a human pathologist; and (2) a human pathologist alone for all biopsies. We found that addition of AI would reduce the pathology workload and save money, and would not affect patient outcomes when compared to a human pathologist alone. The results suggest that adding AI to prostate pathology in Sweden would save costs.

背景和目的:基于图像的人工智能(AI)方法在前列腺癌(PCa)检测中表现出很高的准确性。与人类病理学家相比,这些方法对患者预后和成本效益的影响尚不清楚。我们的目的是评估瑞典 PCa 诊断中人工智能辅助病理学的有效性和成本效益:方法:我们从医疗保健角度出发,对 50 至 74 岁男性进行了四年一次的前列腺特异性抗原(PSA)筛查。前列腺特异性抗原(PSA)≥3 纳克/毫升的男性被转诊进行标准活检(SBx),通过人工智能检查核心,然后由病理学家对人工智能标记的阳性核心进行检查,或者仅由病理学家进行检查。人工智能的性能特征是通过内部 STHLM3 验证数据集估算出来的。结果衡量指标包括检测次数、PCa发病率和死亡率、过度诊断、质量调整生命年(QALYs),以及如果使用人工智能,病理学家评估的活检核心可能减少的数量。成本效益采用增量成本效益比进行评估:与病理学家单独操作相比,人工智能辅助工作流程使PSA检测、SBx手术和PCa死亡人数增加了≤0.03%,并略微降低了PCa发病率和过度诊断率。人工智能可将由病理学家评估的活检核心比例降低 80%。每例病例的成本为10欧元,人工智能辅助工作流程的成本更低,并能带来结论和临床影响:患者摘要:我们比较了瑞典前列腺癌患者的治疗效果和评估前列腺活检的两种方法的相关成本:(1)人工智能(AI)技术和由人类病理学家审查阳性活检;(2)由人类病理学家单独进行所有活检。我们发现,与仅由人类病理学家进行活检相比,增加人工智能可减少病理工作量并节省费用,而且不会影响患者的治疗效果。结果表明,在瑞典的前列腺病理检查中加入人工智能将节约成本。
{"title":"Effectiveness and Cost-effectiveness of Artificial Intelligence-assisted Pathology for Prostate Cancer Diagnosis in Sweden: A Microsimulation Study.","authors":"Xiaoyang Du, Shuang Hao, Henrik Olsson, Kimmo Kartasalo, Nita Mulliqi, Balram Rai, Dominik Menges, Emelie Heintz, Lars Egevad, Martin Eklund, Mark Clements","doi":"10.1016/j.euo.2024.05.004","DOIUrl":"https://doi.org/10.1016/j.euo.2024.05.004","url":null,"abstract":"<p><strong>Background and objective: </strong>Image-based artificial intelligence (AI) methods have shown high accuracy in prostate cancer (PCa) detection. Their impact on patient outcomes and cost effectiveness in comparison to human pathologists remains unknown. Our aim was to evaluate the effectiveness and cost-effectiveness of AI-assisted pathology for PCa diagnosis in Sweden.</p><p><strong>Methods: </strong>We modeled quadrennial prostate-specific antigen (PSA) screening for men between the ages of 50 and 74 yr over a lifetime horizon using a health care perspective. Men with PSA ≥3 ng/ml were referred for standard biopsy (SBx), for which cores were either examined via AI followed by a pathologist for AI-labeled positive cores, or a pathologist alone. The AI performance characteristics were estimated using an internal STHLM3 validation data set. Outcome measures included the number of tests, PCa incidence and mortality, overdiagnosis, quality-adjusted life years (QALYs), and the potential reduction in pathologist-evaluated biopsy cores if AI were used. Cost-effectiveness was assessed using the incremental cost-effectiveness ratio.</p><p><strong>Key findings and limitations: </strong>In comparison to a pathologist alone, the AI-assisted workflow increased the number of PSA tests, SBx procedures, and PCa deaths by ≤0.03%, and slightly reduced PCa incidence and overdiagnosis. AI would reduce the proportion of biopsy cores evaluated by a pathologist by 80%. At a cost of €10 per case, the AI-assisted workflow would cost less and result in <0.001% lower QALYs in comparison to a pathologist alone. The results were sensitive to the AI cost.</p><p><strong>Conclusions and clinical implications: </strong>According to our model, AI-assisted pathology would significantly decrease the workload of pathologists, would not affect patient quality of life, and would yield cost savings in Sweden when compared to a human pathologist alone.</p><p><strong>Patient summary: </strong>We compared outcomes for prostate cancer patients and relevant costs for two methods of assessing prostate biopsies in Sweden: (1) artificial intelligence (AI) technology and review of positive biopsies by a human pathologist; and (2) a human pathologist alone for all biopsies. We found that addition of AI would reduce the pathology workload and save money, and would not affect patient outcomes when compared to a human pathologist alone. The results suggest that adding AI to prostate pathology in Sweden would save costs.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141093309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Re: Guillaume Ploussard, Eric Barret, Gaëlle Fiard, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsies for Prostate Cancer Diagnosis: Final Results of the Randomized PERFECT trial (CCAFU-PR1). Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2024.01.019. Re:Guillaume Ploussard、Eric Barret、Gaëlle Fiard 等:经会阴与经直肠磁共振成像靶向活检诊断前列腺癌:随机 PERFECT 试验 (CCAFU-PR1) 的最终结果。欧洲泌尿肿瘤杂志》。https://doi.org/10.1016/j.euo.2024.01.019.
IF 8.2 1区 医学 Q1 ONCOLOGY Pub Date : 2024-05-20 DOI: 10.1016/j.euo.2024.05.002
Fu-Xiang Lin, Yi Yu, Zhan-Ping Xu
{"title":"Re: Guillaume Ploussard, Eric Barret, Gaëlle Fiard, et al. Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsies for Prostate Cancer Diagnosis: Final Results of the Randomized PERFECT trial (CCAFU-PR1). Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2024.01.019.","authors":"Fu-Xiang Lin, Yi Yu, Zhan-Ping Xu","doi":"10.1016/j.euo.2024.05.002","DOIUrl":"https://doi.org/10.1016/j.euo.2024.05.002","url":null,"abstract":"","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":""},"PeriodicalIF":8.2,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141075905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European urology oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1